U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C50H67N7O8
Molecular Weight 894.111
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMBITASVIR

SMILES

CC(C)[C@@]([H])(C(=O)N1CCC[C@@]1([H])C(=O)Nc2ccc(cc2)[C@]3([H])CC[C@@]([H])(c4ccc(cc4)NC(=O)[C@]5([H])CCCN5C(=O)[C@]([H])(C(C)C)N=C(O)OC)N3c6ccc(cc6)C(C)(C)C)N=C(O)OC

InChI

InChIKey=PIDFDZJZLOTZTM-KHVQSSSXSA-N
InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1

HIDE SMILES / InChI

Molecular Formula C50H67N7O8
Molecular Weight 894.111
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Ombitasvir (ABT-267) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6. In 2015, it was approved by FDA for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1.

CNS Activity

Curator's Comment:: Tissue distribution in rats was slow and did not permeate across the blood brain barrier or into the lens of the eye.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIEKIRA PAK (COPACKAGED)

Approved Use

VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.

Launch Date

1.4189472E12
Primary
TECHNIVIE

Approved Use

TECHNIVIE is a fixed-dose combination of ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.

Launch Date

1.437696E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
68 ng/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1000 ng × h/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23 h
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED

Sample Use Guides

The direct-acting antiviral regimen of 25 mg ombitasvir-150 mg paritaprevir-100 mg ritonavir once daily (QD) plus 250 mg dasabuvir twice daily (BID) is approved for the treatment of hepatitis C virus genotype 1 infection, including patients coinfected with human immunodeficiency virus.
Route of Administration: Oral
In vitro studies revealed that ABT-267 (ombitasvir) is a broad genotype NS5A inhibitor with antiviral activity in the picomolar range (EC50 1.7 -- 19.3 in genotype 1a, 1b, 2a, 3a, 4a and 5a, and 366 pM in genotype 6a).
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:52:33 UTC 2021
Edited
by admin
on Sat Jun 26 05:52:33 UTC 2021
Record UNII
2302768XJ8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMBITASVIR
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
OMBITASVIR [INN]
Common Name English
OMBITASVIR [MI]
Common Name English
OMBITASVIR [VANDF]
Common Name English
OMBITASVIR [ORANGE BOOK]
Common Name English
VIEKIRAX COMPONENT OMBITASVIR
Brand Name English
ABT-267
Code English
CARBAMIC ACID, N,N'-(((2S,5S)-1-(4-(1,1-DIMETHYLETHYL)PHENYL)-2,5-PYRROLIDINEDIYL)BIS(4,1-PHENYLENEIMINOCARBONYL-(2S)-2,1-PYRROLIDINEDIYL((1S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL)))BIS-, C,C'-DIMETHYL ESTER
Systematic Name English
OMBITASVIR [USAN]
Common Name English
OMBITASVIR [WHO-DD]
Common Name English
OMBITASVIR COMPONENT OF VIEKIRAX
Brand Name English
Classification Tree Code System Code
WHO-ATC J05AP53
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
WHO-ATC J05AX67
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
FDA ORPHAN DRUG 484715
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
NCI_THESAURUS C281
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
WHO-ATC J05AP52
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
EMA ASSESSMENT REPORTS VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
FDA ORPHAN DRUG 509215
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
NDF-RT N0000191256
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
Code System Code Type Description
PUBCHEM
54767916
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
DRUG CENTRAL
4912
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
NCI_THESAURUS
C123878
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
RXCUI
1597371
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY RxNorm
FDA UNII
2302768XJ8
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
DRUG BANK
DB09296
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
WIKIPEDIA
Ombitasvir
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
LACTMED
Ombitasvir
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
EVMPD
SUB131058
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
NDF-RT
N0000191272
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY UGT1A1 Inhibitors [MoA]
MERCK INDEX
M11829
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
INN
9740
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
ChEMBL
CHEMBL3127326
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
CAS
1258226-87-7
Created by admin on Sat Jun 26 05:52:33 UTC 2021 , Edited by admin on Sat Jun 26 05:52:33 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
URINE
EXCRETED UNCHANGED
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC